PhoenixBio Co., Ltd.

Equities

6190

JP3803010002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 31/05/2024 BST			5-day change	1st Jan Change
479 ^JPY	-1.24%		-2.84%	+2.79%

2023	PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
2022	PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	CI

PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.

May 12, 2022

PhoenixBio Co., Ltd. announced a private placement of 24,000 4th Stock Acquisition Rights at an issue price of ¥80 per Stock Acquisition Right for gross proceeds of ¥ 1,920,000 on May 13, 2022. The company will issue Stock Acquisition Rights through Third-Party allotment. The initial exercise price is ¥249.

The transaction will include participation from Milestone Capital Management Co., Ltd.

Latest news about PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	15/05/23	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	12/05/22	CI
Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering	06/04/21	CI
PhoenixBio Co., Ltd. announced that it has received ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	29/03/20	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	12/03/20	CI
PhoenixBio Co., Ltd. completed the acquisition of KMT Hepatech Inc. from a group of shareholders.	30/11/17	CI
PhoenixBio Co., Ltd. agreed to acquire KMT Hepatech Inc. from a group of shareholders for CAD 5.5 million.	13/11/17	CI
Certain shares of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	12/09/16	CI
Certain warrants of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	12/09/16	CI
PhoenixBio Co., Ltd. has completed an IPO in the amount of ¥984.00 million.	17/03/16	CI
PhoenixBio Co., Ltd. has filed an IPO.	15/02/16	CI

Chart PhoenixBio Co., Ltd.

Duration

Period

More charts

Company Profile

PhoenixBio Co., Ltd. is a Japan-based company mainly engaged in provision of contract research services of drug development, which uses PXB mouse. The PXB Mouse segment is engaged in the development of technology to create PXB Mouse in which more than 70% of mouse livers are replaced with human hepatocytes. The product called PXB Mouse is used in the preclinical process of the discovery of drugs.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PHOENIXBIO CO., LTD.	+2.79%	12.27M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research